{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:54:51Z","timestamp":1769208891881,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To explore associations between preterm birth and use of medications in young adulthood as a proxy for different diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We linked data on birth characteristics from the Medical Birth Registry of Norway (1967\u20131999) and the Norwegian Prescription Database (2004\u20132015). Individuals born as singletons during 1974\u20131984 and alive at the age of 31 were included (main analyses) (<jats:italic>n<\/jats:italic>\u00a0=\u00a0450\u00a0555). Relative risks (RRs) with 95% confidence intervals (CIs) of using different medications were estimated by log\u2010binomial regression. Population attributable risk and attributable risk percentage (PAR% and AR%) due to preterm birth were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Individuals born preterm used more specific medications at age 30 than those born at term. The risks of being dispensed psychotropic medications overall and the subgroups antiepileptics, antipsychotics, anxiolytics and hypnotics were elevated in individuals born preterm. For attention\u2010deficit\/hyperactivity disorder medications, the risk was elevated in males born extremely preterm (RR 5.8; 95%CI: 2.2\u201315). The risk of being dispensed antiasthmatics increased by shorter gestational ages. For psychotropic medications, PAR% was 0.6% in males and 0.7% in females at age 30; AR% was 13% in males and 17% in females. For antiasthmatics, the corresponding figures were 1.4, 1.1, 24 and 23%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Individuals born preterm used more psychotropic medications overall and antiasthmatics around age 30 than those born at term. The proportions using these medications increased for those born at earlier gestational ages. Those born preterm, especially before 32\u00a0weeks of gestation, should be given special attention during early adulthood regarding development of symptoms and signs of certain diseases. Copyright \u00a9 2017 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4174","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T08:40:14Z","timestamp":1486456814000},"page":"742-751","source":"Crossref","is-referenced-by-count":10,"title":["Preterm births and use of medication in early adulthood: a population\u2010based registry study"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-9207","authenticated-orcid":false,"given":"Anders","family":"Engeland","sequence":"first","affiliation":[{"name":"Department of Pharmacoepidemiology Norwegian Institute of Public Health  Bergen\/Oslo Norway"},{"name":"Department of Global Public Health and Primary Care University of Bergen  Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tone","family":"Bj\u00f8rge","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care University of Bergen  Bergen Norway"},{"name":"Cancer Registry of Norway  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Klungs\u00f8yr","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care University of Bergen  Bergen Norway"},{"name":"Department of Health Registers Norwegian Institute of Public Health  Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[{"name":"Department of Mental Disorders Norwegian Institute of Public Health  Oslo Norway"},{"name":"Norwegian Centre for Addictive Research University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology Norwegian Institute of Public Health  Bergen\/Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"WHO.Preterm birth2016[Available from:http:\/\/www.who.int\/mediacentre\/factsheets\/fs363\/en[accessed January 14 2017]."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(08)60074\u20104"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60136-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdevneu.2011.04.004"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.7.2011060"},{"key":"e_1_2_10_7_1","unstructured":"The Medical Birth Registry of Norway.The Medical Birth Registry of Norway2016. [Available from:http:\/\/statistikkbank.fhi.no\/mfr\/[accessed January 14 2017]."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.08.020"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3002"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.11.013"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1279"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1289"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12430"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12170"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj\u20102014\u2010206590rep"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706475"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.2107"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10\u20102108"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010\u20102603"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318231528f"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"e_1_2_10_22_1","unstructured":"WHOCollaborating Centre for Drug Statistics Methodology 2010."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2000.079006435.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2000.079006440.x"},{"key":"e_1_2_10_25_1","unstructured":"Statistics Norway;2016[updated 2016. Available from:ssb.no(last accessed January 14 2017)."},{"key":"e_1_2_10_26_1","unstructured":"BhopalR.Concepts of epidemiology3 ed.2005;209\u201310."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u201012\u201096"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117253"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq103"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1331"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291714001998"},{"key":"e_1_2_10_32_1","first-page":"129","article-title":"Establishment of the nationwide Norwegian Prescription Database (NorPD)\u2014new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"Furu K","year":"2008","journal-title":"Nor J Epidemiol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12868"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:33:38Z","timestamp":1696505618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/pds.4174"],"URL":"https:\/\/doi.org\/10.1002\/pds.4174","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}